Drug Trial Radar · NCT05510544
Plerixafor for Poorly Mobilized Lymphoma
Last checked: Nov 20, 2026Latest source record: Mar 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Dec 19, 2022
Primary completion
Dec 20, 2023
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- Peking UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Autologous hematopoietic stem cell transplantation is one of the effective means of lymphoma treatment, but patients who receive transplantation in the absence of sufficient stem cell numbers have a delay in stem cell engraftment and a markedly increased risk of infection and emergence. Plerixafor injection is a strong and specific antagonist of CXCR4. It can rapidly mobilize stem cells from bone marrow into peripheral blood circulation by blocking the combination of SDF1 and CXCR4. Studies have shown that the simultaneous use of plerixafor injection and G-CSF can collect more hematopoietic stem cells in a certain period of time than cancer patients who use G-CSF alone. This multicenter, open-label, single-arm study was designed to evaluate the efficacy and safety of plerixafor injection for hematopoietic stem cell mobilization in poorly mobilized lymphoma patients.
Conditions
- Lymphoma
Interventions
Plerixafor,G-CSFDrug
G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8. Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the proportion of patients achieving ≥2 × 10ˆ6/kg CD34+ HSCs within ≤4 apheresis sessions.Time frame: within 4 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.